XJPX
9729
Market cap495mUSD
Oct 09, Last price
2,589.00JPY
1D
2.13%
1Q
7.16%
Jan 2017
29.94%
Name
Tokai Corp (Gifu)
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1955 and headquartered in Gifu, Japan, TOKAI Corp. offers a comprehensive suite of services throughout Japan, centered around enhancing the quality of life. Within the healthcare sector, the company is a key provider, offering rental solutions for hospital bedding and lab coats, handling in-hospital logistics, supplying linens, and providing nursing support. They also facilitate long-term care by supplying and renting essential equipment. A diverse food service line, including regular, therapeutic, and soft meal options, along with the management of dispensing pharmacies, further supports health-related needs. Expanding beyond direct patient care, TOKAI Corp. furnishes bedding and linens for hotels and various accommodation providers. The company also manufactures and markets cleaning equipment. Additionally, TOKAI Corp. reaches homes and offices with water delivery services under the Aqua Clara brand. They provide building maintenance specifically for medical and welfare institutions and manage information distribution services. Their environmental focus includes the rental and sale of beautification products under the Leeskin brand, alongside the development and commercialization of solar power plant facilities.
Key people
Koji Onogi
Chairman of the Board, Representative Director · since 2023
Eiko Matsuno
President of Subsidiary, Director · since 2019
Seiji Funasaka
Executive Officer, Chief Director of Bedclothes & Linen Supply Business · since 2023
Hirokazu Hori
Executive Officer, President of Subsidiary · since 2023
Masayasu Katagiri
Executive Officer, Chief Director of Silver Business · since 2024
Masashi Katano
Executive Officer, Chief Director in charge of Silver Business Promotion, President of Subsidiaries · since 2024
Tadahira Kawakami
Executive Officer, Chief Director of Business Development, Director of Business Development · since 2025
Takayuki Matsuo
Executive Officer, President of Subsidiary · since 2022
Minoru Matsuzaki
Executive Officer, Chief Director of Production, President of Subsidiary · since 2022
Toru Murakami
Executive Officer, President of Subsidiary · since 2014
Kiyoshi Sawamura
Executive Officer, Chief Director of Human Resources · since 2023
Masahiro Sugiyama
Executive Officer, Chief Director in charge of Eastern in Main Hospital Related Business Unit · since 2023
Shinji Takagi
Executive Officer, Chief Director of General Affairs and System, President of Subsidiary · since 2025
Hisaaki Uematsu
Executive Officer, Chief Director of Leeskin Business, President of Subsidiary · since 2023
Masaru Wada
Executive Officer, Chief Director of L.E.C, Director of Sales, President of Subsidiary · since 2025
Tsuyoshi Yokokawa
Executive Officer, President of Subsidiary · since 2024
Kenji Yoshida
Executive Officer, Chief Director of Finance and Planning, Director of Business Planning · since 2024
Toshiaki Asai
President, Representative Director · since 2023
Tomoyoshi Asano
Director · since 2025
Toshimitsu Muraki
Director · since 2022
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||